Europe’s biggest cancer congress ESMO wraps up today, having delivering its fair share of major studies and talking points in cancer treatment over five days.
Cellectis’ 'off the shelf' CAR-T cancer therapy has hit a major setback after the first patient treated in a phase 1 study died, and the first patient treated in another developed life-thr